Shares of Clearpoint Neuro sank 12.3% to $14.00 on August 20 as investors continued to punish the medical-device maker for second-quarter results that fell well short of expectations — and a guidance cut that signals the road to profitability just got longer.
A Revenue Miss That Wasn't Even Close
The company reported Q2 2026 revenue of $10.9 million, up 18% year-over-year but $1.83 million below the $12.73 million consensus estimate.
Earnings per share came in at -$0.38, compared to -$0.21 a year ago , missing Wall Street's -$0.29 estimate by 31%. That double miss — on revenue and losses — leaves no line for bulls to hide behind. Shares initially plunged 15.47% in after-hours trading following the August 3 report , and today's selloff shows the damage isn't over.
The Drug-Delivery Engine Stalled The most alarming signal sits inside the company's biologics and drug-delivery segment — the business management has called its top priority for a decade. That segment's revenue declined 15% to $4.0 million, mainly because a large prior-year customer order did not repeat.
Neurosurgery navigation revenue grew 64.7% to $5.6 million , but that line was boosted by the recent IRRAS acquisition, masking organic weakness.
Spending Rose Fast, Guidance Went the Other Way
Operating expenses surged 51% to $17.0 million, expanding the operating loss to $10.2 million and net loss to $11.3 million. Management blamed the IRRAS integration and larger clinical teams. Meanwhile, the company entered 2026 guiding to $52–$56 million in full-year revenue ; it now projects just $48–$52 million, citing a shift in priorities toward clinical support and new technology development. That's a $4 million haircut at the midpoint.
The Cash Runway Is Getting Shorter
Clearpoint ended June with $29.4 million in cash, down from $45.9 million at year-end 2025. Burning roughly $16 million in six months while posting an $11 million quarterly loss gives the company perhaps four to five quarters of runway before it needs fresh capital — diluting existing shareholders — or a dramatic spending reversal. Management still targets $500 million in long-term annual revenue , but at today's pace, that ambition looks more like a financing risk than a growth story.